RobertMDS Patient

The Right Expression Can Change a Life

When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control gene expression, we aim to make a profound difference in patients’ lives. We are advancing a pipeline of investigational medicines for cancers that have largely eluded other genomics-based approaches.

Tamibarotene

Tamibarotene (formerly SY-1425) is an oral selective retinoid acid receptor alpha (RARα) agonist in clinical development for genomically defined subsets of patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.

View Program

SY-2101

SY-2101 is a novel oral form of arsenic trioxide (ATO) in clinical development for patients with acute promyelocytic leukemia.

View Program

SY-5609

SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor that is in clinical development for patients with pancreatic cancer and BRAF-mutant colorectal cancer.

View Program

Interested in Externally Sponsored Research?

Externally Sponsored Research (ESR) can play a role in expanding the knowledge related to a company product and/or its associated disease area(s). Syros encourages submissions from qualified investigators by filling out our form. Once submitted, a member of our medical affairs team will contact you with information on our review process.

Submit Your Request

Interested in Participating in a Clinical Trial?

If you’re interested in participating in a clinical trial, check to see if a trial is open near your area and if you meet the requirements to participate.

Learn More

Partnership Opportunities

We seek partnerships that maximize value for our partners and us. We are exploring out-licensing opportunities for our SY-5609 program, an oral reversible inhibitor of CDK7 with best-in-class selectivity and potency, enabling broad development potential. We are also exploring out-licensing opportunities for our preclinical oncology programs consisting of potential first-in-class and best-in-class assets.

View Our Partnership Focus

Our Publications and Abstracts

Learn more about the science and data behind our platform and our programs.

Read Publications and Abstracts